Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

Annals of the Rheumatic Diseases(2025)10.1016/j.ard.2025.02.012Source: DataRank Database

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial is a research paper published in Annals of the Rheumatic Diseases (2025). On theSindex it has a DataRank of 0. It has been cited 26 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

26 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 22.35)OA: closedTopics (32)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Mimi Kim ORCID,Marta Guerra ORCID,Joseph Worden,Carl A. Laskin ORCID,Maria T. DeSancho ORCID

Live enrichment

PubMed:40483169 OpenAlex:https://openalex.org/W4409329618

UCB

Grant: 00094818

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: R21AR069189

UCB US

Grant: UL1 TR 002538

Lupus Foundation of America

Morris and Alma Schapiro Fund

National Institutes of Health

University of Utah

National Center for Advancing Translational Sciences

FWCI

22.35

Citation Percentile

1.0%

Citation Trend

2025

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S0003496725002432?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0003496725002432?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ard.2025.02.012

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40483169

Fields of Study

Systemic Lupus Erythematosus ResearchPregnancy and Medication ImpactPregnancy and preeclampsia studies

MeSH Terms

Certolizumab PegolAdultAspirinDrug Therapy, CombinationFemaleFetal DeathHeparin, Low-Molecular-WeightHumansImmunosuppressive AgentsPolyethylene GlycolsPre-EclampsiaPregnancyPregnancy ComplicationsPregnancy OutcomeProspective StudiesLupus Coagulation InhibitorAntiphospholipid SyndromeTreatment Outcome

Keywords

MedicineCertolizumab pegolAntiphospholipid syndromeLupus anticoagulantOpen labelAdverse effectPregnancyInternal medicineThrombosisRheumatoid arthritisAdalimumab

Sustainable Development Goals

SDG 0: Good health and well-being

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

FAIR Checklist

Authors (11)

Funding (8 grants)

Impact

Open Access

Topics